All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing key data from the phase IV EMBRACE trial (NCT03774875), which investigated the efficacy and safety of apremilast in patients with plaque psoriasis and involvement of at least one special area (dorsal hand, face, neck or hairline, scalp, nails, genital areas, or palmoplantar areas). This was a randomized, placebo-controlled trial, which compared apremilast 30 mg twice daily for 16 weeks to placebo.1
We have previously published a visual abstract on the use of apremilast in patients with mild-moderate plaque psoriasis (the ADVANCE trial) and an article about the 5-year safety of apremilast in psoriasis and psoriatic arthritis.
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox